Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Drug safety

TNF-α antagonists not linked with cancer in Danish study

The use of tumour necrosis factor alpha (TNF-α) antagonists to treat inflammatory bowel disease (IBD) is not associated with an increased risk of cancer, analysis of a Danish registry indicates[1].

The analysis, conducted by researchers from Statens Serum Institute and Herlev University Hospital, both in Copenhagen, compared the incidence of cancer among 56,146 patients with IBD, 8.1% of whom were exposed to, on average, eight doses of TNF-α antagonists.

Over a median follow up of 3.7 years, 81 of the 4,553 patients exposed to TNF-α antagonists developed cancer, but these patients were no more likely to develop cancer than patients not exposed to the treatment.

The researchers concede that the relatively small sample size and low number of cancer cases mean that an increased risk of cancer in the long-term or with increasing dosages cannot be excluded.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20065561

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.